Cardinal Health shares climbed 2.83% during the latest trading session, bucking a broader market downturn in which the S&P 500 fell by 0.9% and the Dow Jones Industrial Average lost 0.7%. Trading volume of roughly 3.1 million shares was 15% above the 30-day daily average, underscoring robust investor interest in the healthcare services provider despite headwinds in other sectors.

At the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference, CEO Jason Hollar disclosed that Cardinal Health now expects adjusted earnings per share of at least $10 in fiscal 2026, up from prior guidance of $9.50. Management cited broad-based market growth in pharmaceutical distribution and accelerated margin improvements in its Specialty Business as key drivers of the higher forecast.

Cardinal Health reaffirmed its plan to generate over $50 billion in Specialty segment revenue in fiscal 2026, representing a compound annual growth rate of approximately 8% from fiscal 2023. The Specialty Business, which serves oncology and other high-complexity treatment areas, delivered year-over-year sales growth of 12% in the most recent quarter, supported by expanded clinic partnerships and new oncology therapy launches.

Management highlighted several initiatives underlying its multiyear growth journey, including the rollout of an advanced analytics platform for inventory optimization, consolidation of distribution centers to realize annualized savings of $150 million and a strategic joint venture to enhance medical device sourcing. These efforts, combined with a disciplined capital allocation framework and a commitment to debt reduction, are aimed at reinforcing both top-line acceleration and cash flow resiliency.